Harvard Bioscience (HBIO) EBT (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of EBT data on file, last reported at -$3.3 million in Q1 2026.

• On a quarterly basis, EBT rose 93.49% year-over-year to -$3.3 million in Q1 2026; TTM through Mar 2026 was -$9.9 million, a 82.93% increase from a year earlier, with the FY2025 full-year figure at -$57.4 million, down 391.95% from the prior year.
• EBT for Q1 2026 stood at -$3.3 million, down from -$3.2 million in the prior quarter.
• Over the last five years, EBT for HBIO reached as high as $3.4 million in Q2 2022 and fell as low as -$50.8 million in Q1 2025.
• Historically, EBT has averaged -$4.9 million across 5 years, with a median of -$2.3 million in 2025.
• On a YoY basis, EBT climbed as much as 641.3% in 2022 and fell as far as 10522.22% in 2022.
• Year by year, EBT stood at -$892000.0 in 2022, then dropped by 23.65% to -$1.1 million in 2023, then jumped by 153.49% to $590000.0 in 2024, then tumbled by 643.05% to -$3.2 million in 2025, then decreased by 3.21% to -$3.3 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$3.3 million in Q1 2026, -$3.2 million in Q4 2025, and -$1.1 million in Q3 2025.